U.K. Spending Watchdog Rejects Avastin Again For Metastatic Colorectal Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche's offer of lump-sum payments to the NHS fails to sway NICE in its second draft evaluation of Avastin for the indication, but because it is not yet a final determination, stakeholders will have an opportunity to weigh in.